| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Department
of Respiratory Medicine, Bart's and the London NHS Trust, St
Bartholomew's Hospital, London EC1A 7BE, UK
Correspondence to: Dr V L C White vlcw{at}btinternet.com
Received 5 January 2000; Returned to authors 29 March 2000; Revised version received 30 June 2000; Accepted for publication 28 July 2000
BACKGROUND
Multidrug
resistant tuberculosis (MDR TB) requires a complex drug regimen and
lengthy multidisciplinary care. The financial cost of successful
management of each case is potentially large.
METHODSThe costs of
managing nine HIV negative patients with pulmonary MDR TB were compared
with 18 age group and ethnicity matched controls with fully sensitive
disease. Calculations included: cost of outpatient visits and inpatient
stays including negative pressure isolation; costs of drug provision
and toxicity monitoring; costs of additional procedures and
multidisciplinary referrals.
RESULTSThe mean cost
of managing a case of pulmonary MDR TB was in excess of £60 000 and
for sensitive disease it was £6040.
CONCLUSIONSClinicians
and healthcare commissioning authorities may both be underestimating
the costs of managing MDR TB, and accordingly the consequences for
units dealing with such cases may be serious. Funding of care for MDR
TB in the UK requires strategic decisions at regional or governmental level.
This article has been cited by other articles:
|
|
 |
|
  O. Danilchanka, C. Mailaender, and M. Niederweis Identification of a Novel Multidrug Efflux Pump of Mycobacterium tuberculosis Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2503 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H Bothamley Tuberculosis and social exclusion: New approach is needed BMJ, July 22, 2006; 333(7560): 200 - 200. [Full Text]
|
|
|
|
 |
|
 B. Y. Lee and E. H. Chen Additional Information Can Enhance Validation of Tuberculosis Isolation Prediction Model Arch Intern Med, August 8, 2005; 165(15): 1794 - 1794. [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Ormerod Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment Br. Med. Bull., June 14, 2005; 73-74(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R D Barker, J Glyn-Jones, and G Bothamley DOT for all patients with smear-positive pulmonary TB in London? J Epidemiol Community Health, March 1, 2003; 57(3): 231 - 231. [Full Text] [PDF]
|
|
|
|
 |
|
 R D Barker, J Glyn-Jones, and G Bothamley DOT for all patients with smear-positive pulmonary TB in London? Thorax, January 1, 2003; 58(1): 91 - 91. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Loddenkemper, D. Sagebiel, and A. Brendel Strategies against multidrug-resistant tuberculosis Eur. Respir. J., July 1, 2002; 20(36_suppl): 66S - 77s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Djuretic, J Herbert, F Drobniewski, M Yates, E G Smith, J G Magee, R Williams, P Flanagan, B Watt, A Rayner, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999 Thorax, June 1, 2002; 57(6): 477 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.D.O. Davies A European framework for effective tuberculosis control Eur. Respir. J., April 1, 2002; 19(4): 590 - 592. [Full Text] [PDF]
|
|
|
|
|
|
G H Bothamley, J P Rowan, C J Griffiths, M Beeks, M McDonald, E Beasley, C van den Bosch, and G Feder Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless Thorax, January 1, 2002; 57(1): 45 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W A GEERLIGS, R VAN ALTENA, and T S VAN DER WERF Systemic effects of inhaled steroids. Thorax, December 1, 2001; 56(12): 980 - 981. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
